Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of vancomycin loading dose on AUC0-24 target attainment in pediatric sepsis patients
TCTR20210617001Phase 4
Key facts
- Status
- Completed
- Start
- Jul 2021
- Countries
- 1
- Sponsor
- Kritsaporn Sujjavorakul
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Drugs
- vancomycin
- Conditions
- sepsis
01
Overview
Phase 4 trial of vancomycin in sepsis, sponsored by Kritsaporn Sujjavorakul. Primary endpoint: AUC0-24 target attainment. Started Jul 2021; status: completed.
02
Who it enrols
Hospitalized pediatric patients in Thailand diagnosed with sepsis and treated with intravenous vancomycin; detailed inclusion and exclusion criteria were not reported.
03
Endpoints
Primary
AUC0-24 target attainment
Beyond the preview
Go deeper on TCTR20210617001.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210617001.